Expression of an activating mutation in the gene encoding the K(ATP) channel subunit Kir6.2 in mouse pancreatic beta cells recapitulates neonatal diabetes


Autoria(s): GIRARD, Christophe A.; WUNDERLICH, F. Thomas; SHIMOMURA, Kenju; COLLINS, Stephan; KAIZIK, Stephan; PROKS, Peter; ABDULKADER, Fernando; CLARK, Anne; BALL, Vicky; ZUBCEVIC, Lejla; BENTLEY, Liz; CLARK, Rebecca; CHURCH, Chris; HUGILL, Alison; GALVANOVSKIS, Juris; COX, Roger; RORSMAN, Patrik; BRUENING, Jens C.; ASHCROFT, Frances M.
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

18/04/2012

18/04/2012

2009

Resumo

Neonatal diabetes is a rare monogenic form of diabetes that usually presents within the first six months of life. It is commonly caused by gain-of-function mutations in the genes encoding the Kir6.2 and SUR1 subunits of the plasmalemmal ATP-sensitive K(+) (K(ATP)) channel. To better understand this disease, we generated a mouse expressing a Kir6.2 mutation (V59M) that causes neonatal diabetes in humans and we used Cre-lox technology to express the mutation specifically in pancreatic beta cells. These beta-V59M mice developed severe diabetes soon after birth, and by 5 weeks of age, blood glucose levels were markedly increased and insulin was undetectable. Islets isolated from beta-V59M mice secreted substantially less insulin and showed a smaller increase in intracellular calcium in response to glucose. This was due to a reduced sensitivity of K(ATP) channels in pancreatic beta cells to inhibition by ATP or glucose. In contrast, the sulfonylurea tolbutamide, a specific blocker of K(ATP) channels, closed K(ATP) channels, elevated intracellular calcium levels, and stimulated insulin release in beta-V59M beta cells, indicating that events downstream of K(ATP) channel closure remained intact. Expression of the V59M Kir6.2 mutation in pancreatic beta cells alone is thus sufficient to recapitulate the neonatal diabetes observed in humans. beta-V59M islets also displayed a reduced percentage of beta cells, abnormal morphology, lower insulin content, and decreased expression of Kir6.2, SUR1, and insulin mRNA. All these changes are expected to contribute to the diabetes of beta-V59M mice. Their cause requires further investigation.

Wellcome Trust

Medical Research Council (MRC), UK

European Union (EuroDia) and (BioSim)[LSHM-CT-2006-518153]

European Union (EuroDia) and (BioSim)[LSHB-CT-2004-05137]

Royal Society

DFG - Deutsche Forschungsgemeinschaft[DGF-BR1492-7]

Conselho Nacional de Desenvolvimento Cientifico a Tecnologico (CNPq), Brazil

Identificador

JOURNAL OF CLINICAL INVESTIGATION, v.119, n.1, p.80-90, 2009

0021-9738

http://producao.usp.br/handle/BDPI/15828

10.1172/JCI35772

http://dx.doi.org/10.1172/JCI35772

Idioma(s)

eng

Publicador

AMER SOC CLINICAL INVESTIGATION INC

Relação

Journal of Clinical Investigation

Direitos

openAccess

Copyright AMER SOC CLINICAL INVESTIGATION INC

Palavras-Chave #INSULIN-SECRETION #RECEPTOR #ISLETS #KCNJ11 #MICE #HYPERGLYCEMIA #PROMOTER #THERAPY #SENSORS #PROTEIN #Medicine, Research & Experimental
Tipo

article

original article

publishedVersion